{"_":"Evaluation of the biodistribution of [Tc]Tc-PSMA-GCK01 SPECT/CT in a prospective, intraindividual comparison with [Ga]PSMA-11 PET/CT for phenotyping in mCRPC prior to PSMA-targeted radioligand therapy.","sup":["99m","68"]}
PSMA-PET/CT已成为前列腺癌管理的重要手段。PET的高分辨率和信噪比在原发分期或生化复发（常表现为微小病灶）中是必需的。PSMA-PET还用于筛选适合接受PSMA靶向放射配体治疗的患者，但扫描仪的可用性日益成为瓶颈。PSMA-SPECT/CT的分辨率可能足以区分PSMA阳性与阴性病变，有助于克服供应限制。这项前瞻性、单中心研究通过个体内头对头比较[Tc]Tc-PSMA-GCK01与[Ga]PSMA-11的体内分布和肿瘤摄取，评估前者在放射配体治疗（RLT）前进行表型分型的适用性。十例晚期转移性前列腺癌患者（中位年龄68岁；范围56-85岁）均接受了未增强的[Ga]PSMA-11 PET/CT和[Tc]Tc-PSMA-GCK01 SPECT/CT扫描，平均时间间隔为6天（±1）。由两名核医学医师在共识下使用球形VOI对恶性病灶和正常器官中的示踪剂摄取进行视觉和半定量评估。与[Tc]Tc-PSMA-GCK01相比，[Ga]PSMA-11在正常器官中显示出更高的摄取趋势。肾脏示踪剂摄取[Ga]PSMA-11显著高于[Tc]Tc-PSMA-GCK01。在唾液腺和肝脏中，两种示踪剂的摄取无统计学显著差异，尽管[Tc]Tc-PSMA-GCK01显示出较低摄取的倾向。我们的研究表明，[Tc]Tc-PSMA-GCK01与[Ga]PSMA-11在正常器官分布（包括肝脏或唾液腺等典型参考器官）方面具有个体内可比性。若仅考虑>2 cm的病灶，[Tc]Tc-PSMA-GCK01 PSMA-SPECT似乎是[Ga]PSMA-11的可行且经济有效的替代方案，可在某些临床环境中用于筛选患者接受或排除PSMA-RLT。
PSMA-PET/CT became an important means for prostate cancer management. The high-resolution and signal-to-noise ratio of PET is mandatory in primary staging or biochemical relapse that often present with tiny lesions. PSMA-PET is also used to select patients for PSMA-targeted radioligand-therapy, but scanner availability increasingly becomes a bottleneck. The resolution of PSMA-SPECT/CT might be sufficient to tailor PSMA positive vs. negative disease and would help overcome supply limitations. This prospective, monocentric study evaluates the biodistribution and tumor uptake of [Tc]Tc-PSMA-GCK01 in an intra-individual head-to-head comparison with [Ga]PSMA-11 to assess its suitability for phenotyping prior to RLT. A cohort of ten patients (median age, 68 y; range, 56-85 y) with advanced-stage, metastatic prostate cancer underwent both unenhanced [Ga]PSMA-11 PET/CT and [Tc]Tc-PSMA-GCK01 SPECT/CT scans with a mean time interval of 6 days (± 1). The tracer uptake in malignant lesions and normal organs was assessed visually and semi-quantitatively using spherical VOIs by two nuclear medicine physicians in consensus. Compared to [Tc]Tc-PSMA-GCK01, [Ga]PSMA-11 displayed a trend toward higher uptake in normal organs. Renal tracer uptake was significantly higher with [Ga]PSMA-11 than with [Tc]Tc-PSMA-GCK01. In the salivary glands and liver, there was no statistically significant difference in uptake between the two tracers, although [Tc]Tc-PSMA-GCK01 displayed a trend toward lower uptake. Our study demonstrates intraindividual comparability of [Tc]Tc-PSMA-GCK01 and [Ga]PSMA-11 with respect to normal-organ distribution including typical reference organs such as the liver or salivary glands. If only lesions > 2 cm are considered, [Tc]Tc-PSMA-GCK01 PSMA-SPECT seems to be a viable, cost-effective alternative to [Ga]PSMA-11 to stratify patients toward or against PSMA-RLT in certain clinical settings.
Emil Novruzov, Eduards Mamlins, Joseph Kabunda, Jens Cardinale, Milani Qebetu, Clemens Kratochwil, et al. {"_":"Evaluation of the biodistribution of [Tc]Tc-PSMA-GCK01 SPECT/CT in a prospective, intraindividual comparison with [Ga]PSMA-11 PET/CT for phenotyping in mCRPC prior to PSMA-targeted radioligand therapy.","sup":["99m","68"]}. EJNMMI research. 2026; doi:10.1186/s13550-026-01501-0.
Emil Novruzov, Eduards Mamlins, Joseph Kabunda, Jens Cardinale, Milani Qebetu, Clemens Kratochwil, et al (2026). {"_":"Evaluation of the biodistribution of [Tc]Tc-PSMA-GCK01 SPECT/CT in a prospective, intraindividual comparison with [Ga]PSMA-11 PET/CT for phenotyping in mCRPC prior to PSMA-targeted radioligand therapy.","sup":["99m","68"]}. EJNMMI research. https://doi.org/10.1186/s13550-026-01501-0
Emil Novruzov, Eduards Mamlins, Joseph Kabunda, Jens Cardinale, Milani Qebetu, Clemens Kratochwil, et al. {"_":"Evaluation of the biodistribution of [Tc]Tc-PSMA-GCK01 SPECT/CT in a prospective, intraindividual comparison with [Ga]PSMA-11 PET/CT for phenotyping in mCRPC prior to PSMA-targeted radioligand therapy.","sup":["99m","68"]}[J]. EJNMMI research, 2026 doi:10.1186/s13550-026-01501-0.
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出